 |
|
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online 2022 Dec 12 DOI: https://doi.org/10.3350/cmh.2022.0357
|
|
Citations to this article as recorded by
 Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters
Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Soon Ho Yoon
European Radiology.2024;[Epub] CrossRef Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clinical and Molecular Hepatology.2023; 29(2): 394. CrossRef Application of attenuation imaging for the detection of fatty liver in potential liver donors
Jae Seok Bae, Dong Ho Lee, Kyung-Suk Suh, Kwang-Woong Lee, Nam-Joon Yi, Suk Kyun Hong
European Journal of Radiology.2023; 166: 110958. CrossRef Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
Angeliki Pappa, Tobias Wenzl
Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni
Journal of Clinical Medicine.2023; 12(18): 6057. CrossRef
|